

Busting Mythconceptions about the FDA's Refuse-to-Accept Policy for Cybersecurity

PLAUSIBLE

BUSTED

CONFIRMED



Garrett Schumacher
Technical Director of Product Security
Valentium

BUILT FOR MEDTECH. TRUSTED BY MEDTECH.

100+

years industry
experience

522k


podcast listeners

200k+

look to us for the
latest in quality

#1

blog and podcast
in the industry



“Best QMS I have ever used...”

This is the easiest eQMS I have used in the 20 years I have been in the Medical Device Industry. *It is simple, intuitive and easy to use...* We are successfully implementing a Quality Culture.

- Director of Regulatory Affairs & Quality Assurance

“Modern QMS Software and Outstanding Customer Service.”



“Demystifying QMS and Regulatory Requirements”



“Makes your QMS Simple and Effective”




How We Are Different

Cybersecurity

Velentium's depth and breadth of development experience, as well as our ability to navigate the constraints of secure medical device development, makes us an industry leader in device security.

Test Systems

Velentium's Subject Matter Experts can design you a custom test system, ranging from fully manual to fully automatic, and everything in between.



Device Development

We are a one-stop for secure design, development, production, and post-market services. See how we can take your device from IP to commercialized product today!


Medical Manufacturing

Let Velentium meet your manufacturing needs with our ISO 13485-certified lean QMS and our design and development experts within arms' reach at all times.

Velentium's Product Security Team


Cybersecurity Consulting Services

- Development Project Assistance
- Product Security Governance
- Post Market Support Services
- Mobile Device Management (MDM) Services
- Embedded Cybersecurity Training
- Custom Consulting Services



Velentium's Product Security Team

- Over the last three years, assisted 80 clients with medical device security and FDA/MDR submission content
- ~100 unique medical device projects
 - Deep brain implants
 - Implanted pumps & stimulators
 - AEDs, pacemakers & ventilators
 - Wearable diagnostic devices
 - Mobile, web & cloud
 - SaMD & ML/AI
 - Diagnostic laboratory equipment



Myth
Cybersecurity is an
IT Problem

BUSTED

OT Security vs. IT Security

IT Security

(Information Technology)

- Confidentiality, Integrity, Availability
- Data and network focused
- Centralized and large well-resourced systems

OT Security

(Operational Technology)

- Safety, Integrity, Availability
- Operational efficacy and reliability
- Distributed, low-resource systems

**Medical
Device
Security**

Myth:

Patients are the Most

Important Stakeholder

CONFIRMED

in Medical
Cybersecurity

Morbidity and Mortality Weekly Report (MMWR)

Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United States, July 2020–July 2021

Weekly / November 19, 2021 / 70(46);1613–1616

Geoffrey French, MA¹; Mary Hulse, MPA¹; Debbie Nguyen²; Katharine Sobotka²; Kaitlyn Webster, PhD²; Josh Corman¹; Brago Aboagye-Nyame²; Marc Dion²; Moira Johnson²; Benjamin Zalinger, MA²; Maria Ewing² ([VIEW AUTHOR AFFILIATIONS](#))

<https://www.cdc.gov/mmwr/volumes/70/wr/mm7046a5.htm>

Hospitals say cyberattacks increase death rates and delay patient care

A new report surveyed healthcare organizations about their experiences

By [Nicole Wetsman](#) | Sep 27, 2021, 3:42pm EDT

<https://www.theverge.com/2021/9/27/22696097/hospital-ransomware-cyberattack-death-rates-patients>

Baby died because of ransomware attack on hospital, suit says

The filing is the first credible public claim that someone's death was caused at least in part by hackers who remotely shut down a hospital's computers.

Sept. 30, 2021, 11:51 AM MDT / Updated Sept. 30, 2021, 5:16 PM MDT

By [Kevin Collier](#)

<https://www.nbcnews.com/news/baby-died-due-ransomware-attack-hospital-suit-claims-rcna2465>

A patient has died after ransomware hackers hit a German hospital

This is the first ever case of a fatality being linked to a cyberattack.

By [Patrick Howell O'Neill](#)

September 18, 2020

<https://www.technologyreview.com/2020/09/18/1008582/a-patient-has-died-after-ransomware-hackers-hit-a-german-hospital/>

Key FDA Terms

- ✓ **“Safety and Efficacy”** – Original FDA medical device mandate
- ✓ **“Reasonable assurance the device and related systems are cybersecurity”** – Omnibus / RTA Policy
- ✓ FDA Panel at DEF CON 31 Biohacking Village Talks
 - Be sure to check their YouTube channel for the recordings to be posted
 - <https://www.youtube.com/@BiohackingVillage>

		“Understanding”	
		Knowns	Unknowns
“Awareness”	Known	Known Knowns	Known Unknowns
	Unknown	Unknown Knowns	Unknown Unknowns

		“Understanding”	
		Knowns	Unknowns
“Awareness”	Known	Things we are aware of and understand	Things we are aware of but do not understand
	Unknown	Things we understand but are not aware of	Things we neither understand nor are aware of




Security Risk Management

1. **Identify potential risks** (awareness)
2. **Analyze and assess risks** (understanding)
3. **Manage risk via:**
 - Accepting it → unreasonable assurance now
 - Reducing it → design and implementation of controls
 - Removing it → making an architectural or design change
 - Transferring it → communication to users, agreements, etc.
4. **Repeat / Maintain**

Various and appropriate ways in which to do this at different stages of the complete product lifecycle


2 Risk Management Paths

- ANSI/AAMI TIR57:2016 (R2023) Principles For Medical Device Security - Risk Management
- ANSI/AAMI SW96:2023 Standard For Medical Device Security - Security Risk Management For Device Manufacturers



AAMI SW96:2023

<https://array.aami.org/doi/10.2345/9781570208621>



AAMI TIR57:2016 (R2023)



<https://webstore.ansi.org/standards/aami/aamitir572016r2023>


Myth.
Medical Device
Security is a New
Problem


BUSTED

A Brief History: US Market


- **1938** – Federal Food, Drug, and Cosmetic Act (FD&C Act)
- **1970s** – Origins of term ‘Cybersecurity’ and field
- **1976** – FDA Medical Device Amendments to ensure safety and effectiveness of medical devices
- **‘90s–‘00s** – Additional requirements, such as post-market surveillance and management of devices
- **2005** – Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (OTS) Software








Aug 2011
Security researcher presents insulin pump vulnerabilities at blackhat





A Brief History: US Market

- **2014** – FDA added security to submissions
- **2016** – FDA requires MDMs to monitor and maintain fielded devices
- ~~**2018** – Updated premarket guidance...~~

JK 😊

GUIDANCE DOCUMENT

Content of Premarket Submissions for Management of Cybersecurity in Medical Devices

Guidance for Industry and Food and Drug Administration Staff

 ~~OCTOBER 2014~~ **2018**

[Download the Final Guidance Document](#)

Final

Docket Number: [FDA-2013-D-0616](#)
Issued by: Center for Devices and Radiological Health

GUIDANCE DOCUMENT

Postmarket Management of Cybersecurity in Medical Devices

Guidance for Industry and Food and Drug Administration Staff

DECEMBER 2016 

[Download the Final Guidance Document](#)

Final

Docket Number: [FDA-2015-D-5105](#)
Issued by: Center for Devices and Radiological Health

A Brief History: US Market

- **April 2022** – FDA releases draft update to premarket guidance

GUIDANCE DOCUMENT

Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions

Draft Guidance for Industry and Food and Drug Administration Staff

APRIL 2022

[Download the Draft Guidance Document](#) [Read the Federal Register Notice](#)

Draft

Not for implementation. Contains non-binding recommendations.

[Share](#) [Tweet](#) [LinkedIn](#) [Email](#) [Print](#)

Docket Number: [FDA-2021-D-1158](#)
Issued by: Center for Devices and Radiological Health
Center for Biologics Evaluation and Research

Content Comparison: 2014 vs 2022

2014 Premarket Guidance

Table of Contents

IV. General Principles & Risk Assessment.....	8
V. Designing a Trustworthy Device: Application of NIST Cybersecurity Framework.....	11
VI. Labeling Recommendations for Devices with Cybersecurity Risks.....	18
VII. Cybersecurity Documentation.....	21

2022 Draft Premarket Guidance

Draft – Not for Implementation

Table of Contents

IV. General Principles.....	4
A. Cybersecurity is Part of Device Safety and the Quality System Regulations.....	4
B. Designing for Security.....	6
C. Transparency.....	6
D. Submission Documentation.....	7
V. Using an SPDF to Manage Cybersecurity Risks.....	8
A. Security Risk Management.....	9
1. Threat Modeling.....	10
2. Third-Party Software Components.....	11
3. Security Assessment of Unresolved Anomalies.....	14
4. Security Risk Management Documentation.....	14
5. TPLC Security Risk Management.....	15
B. Security Architecture.....	16
1. Implementation of Security Controls.....	17
2. Security Architecture Views.....	19
(a) Global System View.....	20
(b) Multi-Patient Harm View.....	20
(c) Updatability and Patchability View.....	21
(d) Security Use Case Views.....	21
C. Cybersecurity Testing.....	22
VI. Cybersecurity Transparency.....	24
A. Labeling Recommendations for Devices with Cybersecurity Risks.....	24
B. Vulnerability Management Plans.....	27

Modern FDA Requirements

- **December 2022** – “Omnibus bill” (Consolidated Appropriations Act, 2023) signed into law
- Adds Section 524B to FD&C Act

GUIDANCE DOCUMENT

Cybersecurity in Medical Devices: Refuse to Accept Policy for Cyber Devices and Related Systems Under Section 524B of the FD&C Act

Guidance for Industry and Food and Drug Administration Staff

MARCH 2023

[Download the Final Guidance Document](#) [Read the Federal Register Notice](#)

Final

[Share](#) [Tweet](#) [LinkedIn](#) [Email](#) [Print](#)

Docket Number: [FDA-2023-D-1030](#)

Issued by: Center for Devices and Radiological Health
Center for Biologics Evaluation and Research

Modern FDA Requirements

- **March 2023** – Omnibus bill became effective

“FDA generally intends not to issue ‘refuse to accept’ decisions for premarket submissions... based solely on information required by section 524B of the FD&C Act before October 1, 2023.”

GUIDANCE DOCUMENT

Cybersecurity in Medical Devices: Refuse to Accept Policy for Cyber Devices and Related Systems Under Section 524B of the FD&C Act

Guidance for Industry and Food and Drug Administration Staff

MARCH 2023

[Download the Final Guidance Document](#) [Read the Federal Register Notice](#)

Final

[Share](#) [Tweet](#) [LinkedIn](#) [Email](#) [Print](#)

Docket Number: [FDA-2023-D-1030](#)

Issued by: Center for Devices and Radiological Health
Center for Biologics Evaluation and Research

Myth:
The FDA's new
authority and
requirements go into
effect October 1, 2023

BUSTED

FD&C Act

Guidance for Industry and Food and Drug Administration Staff

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

I. Introduction

On December 29, 2022, the Consolidated Appropriations Act, 2023 (“Omnibus”) was signed into law. Section 3305 of the Omnibus — “Ensuring Cybersecurity of Medical Devices” — amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) by adding section 524B, Ensuring Cybersecurity of Devices. The Omnibus states that the amendments to the FD&C Act shall take effect 90 days after the enactment of this Act on March 29, 2023. As provided by the Omnibus, the cybersecurity requirements do not apply to an application or submission submitted to the Food and Drug Administration (FDA) before March 29, 2023.

Myth:
Legacy devices or
devices already
approved are not
subject to the new FDA
requirements

CONFIRMED

FD&C Act


Guidance for Industry and Food and Drug Administration Staff

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

I. Introduction

On December 29, 2022, the Consolidated Appropriations Act, 2023 (“Omnibus”) was signed into law. Section 3305 of the Omnibus — “Ensuring Cybersecurity of Medical Devices” — amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) by adding section 524B, Ensuring Cybersecurity of Devices. The Omnibus states that the amendments to the FD&C Act shall take effect 90 days after the enactment of this Act on March 29, 2023. As provided by the Omnibus, the cybersecurity requirements do not apply to an application or submission submitted to the Food and Drug Administration (FDA) before March 29, 2023.

Modern FDA Requirements



II. Policy

Effective March 29, 2023, the FD&C Act is amended to include section 524B “Ensuring Cybersecurity of Devices.” Among section 524B’s cybersecurity provisions are:

- (a) IN GENERAL.—A person who submits an application or submission under section 510(k), 513, 515(c), 515(f), or 520(m) for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements under subsection (b).
- (b) The sponsor of an application or submission described in subsection (a) shall—
 - (1) submit to the Secretary a plan to monitor, identify, and address, as appropriate, in a reasonable time, postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure and related procedures;
 - (2) design, develop, and maintain processes and procedures to provide a reasonable assurance that the device and related systems are cybersecurity, and make available postmarket updates and patches to the device and related systems to address—
 - (A) on a reasonably justified regular cycle, known unacceptable vulnerabilities; and
 - (B) as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks;
 - (3) provide to the Secretary a software bill of materials, including commercial, open-source, and off-the-shelf software components; and
 - (4) comply with such other requirements as the Secretary may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecurity.
- (c) DEFINITION.—In this section, the term ‘cyber device’ means a device that—
 - (1) includes software validated, installed, or authorized by the sponsor as a device or in a device;
 - (2) has the ability to connect to the internet; and
 - (3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

For premarket submissions submitted for cyber devices before October 1, 2023, FDA generally intends not to issue “refuse to accept” (RTA) decisions based solely on information required by section 524B of the FD&C Act. Instead, FDA intends to work collaboratively with sponsors of such premarket submissions as part of the interactive and/or deficiency review process. Beginning October 1, 2023, FDA expects that sponsors of cyber devices will have had sufficient time to prepare premarket submissions that contain information required by section 524B of the FD&C Act, and FDA may RTA premarket submissions that do not. For information about FDA’s RTA policy more generally, sponsors of cyber devices should consult FDA’s guidance documents, [Refuse to Accept Policy for 510\(k\)s](#),¹ [Acceptance and Filing Reviews for Premarket Approval Applications \(PMAs\)](#),² and [Acceptance Review for De Novo Classification Requests](#).³

Modern FDA Requirements

(c) DEFINITION.—In this section, the term ‘cyber device’ means a device that—

- (1) includes software validated, installed, or authorized by the sponsor as a device or in a device;
- (2) has the ability to connect to the internet; and
- (3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

- ✓ Must prove that a device does not have cyber risks as opposed to justifying or claiming it does not

II. Policy

Effective March 29, 2023, the FD&C Act is amended to include section 524B “Ensuring Cybersecurity of Devices.” Among section 524B’s cybersecurity provisions are:

(a) IN GENERAL.—A person who submits an application or submission under section 510(k), 513, 515(c), 515(f), or 520(m) for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements under subsection (b).

(b) The sponsor of an application or submission described in subsection (a) shall—
(1) submit to the Secretary a plan to monitor, identify, and address, as appropriate,

exploits,
etc.;
vide a
secure, and
related systems
table
that could
commercial,
device through
regulation to demonstrate reasonable assurance that the device and related systems are cybersecurity.

(c) DEFINITION.—In this section, the term ‘cyber device’ means a device that—


- (1) includes software validated, installed, or authorized by the sponsor as a device or in a device;
- (2) has the ability to connect to the internet; and
- (3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

For premarket submissions submitted for cyber devices before October 1, 2023, FDA generally intends not to issue “refuse to accept” (RTA) decisions based solely on information required by section 524B of the FD&C Act. Instead, FDA intends to work collaboratively with sponsors of such premarket submissions as part of the interactive and/or deficiency review process. Beginning October 1, 2023, FDA expects that sponsors of cyber devices will have had sufficient time to prepare premarket submissions that contain information required by section 524B of the FD&C Act, and FDA may RTA premarket submissions that do not. For information about FDA’s RTA policy more generally, sponsors of cyber devices should consult FDA’s guidance documents, [Refuse to Accept Policy for 510\(k\), Acceptance and Filing Reviews for Premarket Approval Applications \(PMA\)](#),⁷ and [Acceptance Review for De Novo Classification Requests](#).⁸

Myth:
**Medical devices that
do not connect to the
Internet do not apply**

What is a cyber device?

- Still a vague description
- Must perform risk assessments to truly know if a device is or is not a cyber device
- Can ask FDA directly regarding your device



The screenshot shows the FDA website's Digital Health Center of Excellence. At the top left is the FDA logo. To the right are search and menu buttons. Below the header is a section titled "IN THIS SECTION" with a dropdown arrow. A breadcrumb trail shows "← Digital Health Center of Excellence". The main content area contains three FAQ items:

- Q1: Who is required to comply with section 524B of the FD&C Act? What types of premarket submissions does this apply to?** (dropdown arrow pointing down)
- Q2: What is a cyber device?** (dropdown arrow pointing up)
A: Section 524B(c) of the FD&C Act defines "cyber device" as a device that (1) includes software validated, installed, or authorized by the sponsor as a device or in a device, (2) has the ability to connect to the internet, and (3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to the cybersecurity threats. **If manufacturers are unsure as to whether their device is a cyber device, they may contact the FDA.**
- Q3: Does this law only apply to future medical devices, rather than retroactively?** (dropdown arrow pointing down)

Modern FDA Requirements

(1) submit to the Secretary a plan to monitor, identify, and address, as appropriate, in a reasonable time, postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure and related procedures;

- ✓ Plans and procedures for Postmarket activities in Premarket submission content
- ✓ Updating, SBOM and other monitoring, incident response, and disclosures and communications

II. Policy

Effective March 29, 2023, the FD&C Act is amended to include section 524B "Ensuring Cybersecurity of Devices." Among section 524B's cybersecurity provisions are:

(a) IN GENERAL.—A person who submits an application or submission under section 510(k), 513, 515(c), 515(f), or 520(n) for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements under subsection (b).

(b) The sponsor of an application or submission described in subsection (a) shall—
(1) submit to the Secretary a plan to monitor, identify, and address, as appropriate,

exploits, vulnerabilities, and related systems

(2) as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks;

(3) provide to the Secretary a software bill of materials, including commercial, open-source, and off-the-shelf software components; and

(4) comply with such other requirements as the Secretary may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecurity.

(c) DEFINITION.—In this section, the term "cyber device" means a device that—
(1) includes software validated, installed, or authorized by the sponsor as a device or in a device;

(2) has the ability to connect to the internet; and

(3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

For premarket submissions submitted for cyber devices before October 1, 2023, FDA generally intends not to issue "refuse to accept" (RTA) decisions based solely on information required by section 524B of the FD&C Act. Instead, FDA intends to work collaboratively with sponsors of such premarket submissions as part of the interactive and/or deficiency review process. Beginning October 1, 2023, FDA expects that sponsors of cyber devices will have had sufficient time to prepare premarket submissions that contain information required by section 524B of the FD&C Act, and FDA may RTA premarket submissions that do not. For information about FDA's RTA policy more generally, sponsors of cyber devices should consult FDA's guidance documents, [Refuse to Accept Policy for 510\(k\), Acceptance, and Filing Reviews for Premarket Approval Applications \(PMA\)](#),² and [Acceptance Review for De Novo Classification Requests](#),³

Modern FDA Requirements

(2) design, develop, and maintain processes and procedures to provide a reasonable assurance that the device and related systems are cybersecure, and

- ✓ Plans and procedures for Premarket development activities
- ✓ Reasonable assurance for cybersecurity throughout complete product lifecycle

II. Policy

Effective March 29, 2023, the FD&C Act is amended to include section 524B "Ensuring Cybersecurity of Devices." Among section 524B's cybersecurity provisions are:

(a) IN GENERAL.—A person who submits an application or submission under section 510(k), 513, 515(c), 515(f), or 520(m) for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements under subsection (b).

(b) The sponsor of an application or submission described in subsection (a) shall—
(1) submit to the Secretary a plan to monitor, identify, and address, as appropriate,

to address—
(A) on a reasonably justified regular cycle, known unacceptable vulnerabilities; and
(B) as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks;

(3) provide to the Secretary a software bill of materials, including commercial, open-source, and off-the-shelf software components; and

(4) comply with such other requirements as the Secretary may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecure.

(c) DEFINITION.—In this section, the term "cyber device" means a device that—

(1) includes software validated, installed, or authorized by the sponsor as a device or in a device;

(2) has the ability to connect to the internet; and

(3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

For premarket submissions submitted for cyber devices before October 1, 2023, FDA generally intends not to issue "refuse to accept" (RTA) decisions based solely on information required by section 524B of the FD&C Act. Instead, FDA intends to work collaboratively with sponsors of such premarket submissions as part of the interactive and/or deficiency review process.

Beginning October 1, 2023, FDA expects that sponsors of cyber devices will have had sufficient time to prepare premarket submissions that contain information required by section 524B of the FD&C Act, and FDA may RTA premarket submissions that do not. For information about FDA's RTA policy more generally, sponsors of cyber devices should consult FDA's guidance documents, [Refuse to Accept Policy for 510\(k\)s](#), [Acceptance and Filing Review for Premarket Approval Applications \(PMA\)](#),² and [Acceptance Review for De Novo Classification Requests](#).³

Modern FDA Requirements

make available postmarket updates and patches to the device and related systems to address—

(A) on a reasonably justified regular cycle, known unacceptable vulnerabilities; and

(B) as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks;

- ✓ Regular update cycles based on platform/device type
- ✓ Timely updates as needed
- ✓ Look to forthcoming Joint Security Plan v2 by HSCC

II. Policy

Effective March 29, 2023, the FD&C Act is amended to include section 524B “Ensuring Cybersecurity of Devices.” Among section 524B’s cybersecurity provisions are:

(a) IN GENERAL.—A person who submits an application or submission under section 510(k), 513, 515(c), 515(f), or 520(m) for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements under subsection (b).

(b) The sponsor of an application or submission described in subsection (a) shall—
(1) submit to the Secretary a plan to monitor, identify, and address, as appropriate,

de a
ecure, and
lated systems

able
hat could

ommercial,

ire through

regulation to demonstrate reasonable assurance that the device and related systems are cybersecurity.

(c) DEFINITION.—In this section, the term “cyber device” means a device that—
(1) includes software validated, installed, or authorized by the sponsor as a device or in a device;
(2) has the ability to connect to the internet; and
(3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

For premarket submissions submitted for cyber devices before October 1, 2023, FDA generally intends not to issue “refuse to accept” (RTA) decisions based solely on information required by section 524B of the FD&C Act. Instead, FDA intends to work collaboratively with sponsors of such premarket submissions as part of the interactive and/or deficiency review process. Beginning October 1, 2023, FDA expects that sponsors of cyber devices will have had sufficient time to prepare premarket submissions that contain information required by section 524B of the FD&C Act, and FDA may RTA premarket submissions that do not. For information about FDA’s RTA policy more generally, sponsors of cyber devices should consult FDA’s guidance documents, [Refuse to Accept Policy for 510\(k\)s, Acceptance and Filing Reviews for Premarket Approval Applications \(PMA\)s](#),² and [Acceptance Review for De Novo Classification Requests](#).³

Modern FDA Requirements

(3) provide to the Secretary a software bill of materials, including commercial, open-source, and off-the-shelf software components; and

- ✓ Machine-readable SBOM of all software components and associated processes (maintain, monitor, share)

II. Policy

Effective March 29, 2023, the FD&C Act is amended to include section 524B "Ensuring Cybersecurity of Devices." Among section 524B's cybersecurity provisions are:

(a) IN GENERAL.—A person who submits an application or submission under section 510(k), 513, 515(c), 515(f), or 520(m) for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements under subsection (b).

(b) The sponsor of an application or submission described in subsection (a) shall—
(1) submit to the Secretary a plan to monitor, identify, and address, as appropriate,

to address—

(A) on a reasonably justified regular cycle, known unacceptable vulnerabilities; and

(B) as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks;

(3) provide to the Secretary a software bill of materials, including commercial, open-source, and off-the-shelf software components; and

(4) comply with such other requirements as the Secretary may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecurity.

(c) DEFINITION.—In this section, the term "cyber device" means a device that—

(1) includes software validated, installed, or authorized by the sponsor as a device or in a device;

(2) has the ability to connect to the internet; and

(3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

For premarket submissions submitted for cyber devices before October 1, 2023, FDA generally intends not to issue "refuse to accept" (RTA) decisions based solely on information required by section 524B of the FD&C Act. Instead, FDA intends to work collaboratively with sponsors of such premarket submissions as part of the interactive and/or deficiency review process. Beginning October 1, 2023, FDA expects that sponsors of cyber devices will have had sufficient time to prepare premarket submissions that contain information required by section 524B of the FD&C Act, and FDA may RTA premarket submissions that do not. For information about FDA's RTA policy more generally, sponsors of cyber devices should consult FDA's guidance documents, [Refuse to Accept Policy for 510\(k\)s, Acceptance and Filing Reviews for Premarket Approval Applications \(PMA\)s](#),³ and [Acceptance Review for De Novo Classification Requests](#).⁴

Modern FDA Requirements

(4) comply with such other requirements as the Secretary may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecure.

FDA official: Draft cybersecurity guidance has 'teeth'

Not following the guidance in premarket submissions means potential delays for device makers, said Suzanne Schwartz, director of CDRH's Office of Strategic Partnerships and Technology Innovation.

Published April 11, 2022

<https://www.medtechdive.com/news/fda-draft-cybersecurity-guidance-requirements/621872/>

II. Policy

Effective March 29, 2023, the FD&C Act is amended to include section 524B "Ensuring Cybersecurity of Devices." Among section 524B's cybersecurity provisions are:

(a) IN GENERAL.—A person who submits an application or submission under section 510(k), 513, 515(c), 515(f), or 520(m) for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements under subsection (b).

(b) The sponsor of an application or submission described in subsection (a) shall—
(1) submit to the Secretary a plan to monitor, identify, and address, as appropriate,

updates, vulnerabilities, and critical vulnerabilities that could cause uncontrolled risks;

(2) provide to the Secretary a software bill of materials, including commercial, open-source, and off-the-shelf software components; and

(4) comply with such other requirements as the Secretary may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecure.

(c) DEFINITION.—In this section, the term "cyber device" means a device that—

(1) includes software validated, installed, or authorized by the sponsor as a device or in a device;

(2) has the ability to connect to the internet; and

(3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

For premarket submissions submitted for cyber devices before October 1, 2023, FDA generally intends not to issue "refuse to accept" (RTA) decisions based solely on information required by section 524B of the FD&C Act. Instead, FDA intends to work collaboratively with sponsors of such premarket submissions as part of the interactive and/or deficiency review process. Beginning October 1, 2023, FDA expects that sponsors of cyber devices will have had sufficient time to prepare premarket submissions that contain information required by section 524B of the FD&C Act, and FDA may RTA premarket submissions that do not. For information about FDA's RTA policy more generally, sponsors of cyber devices should consult FDA's guidance documents, [Refuse to Accept Policy for 510\(k\)s, Acceptance and Filing Reviews for Premarket Approval Applications \(PMA\)s](#),² and [Acceptance Review for De Novo Classification Requests](#).³

Myth:
There must be an
explicit link between
security and safety for
the FDA to have
authority





U.S. Department of Health and Human Services



SAFETY
+
EFFICACY

“The FDA... ensures that... medical devices are safe and effective...”



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office for Civil Rights



HIPAA
Health Insurance Portability
Privacy & Accountability Act

“OCR ensures that... individuals can access and trust the privacy and security of their health information.”

Shifting Sands of MedTech Security

- No longer an explicit link between safety and security required for FDA authority
 - Security alone is enough
- Plus, many other regulatory bodies are joining the party...

HIPAA Violations


- \$100 to \$250,000 fine per incident
- Largest to-date: \$16 million due to data breach
- Common HIPAA violations:
 1. Snooping on Healthcare Records
 2. Failure to Perform an Organization-Wide Risk Analysis
 3. Failure to Manage Security Risks / Lack of a Risk Management Process
 4. Insufficient ePHI Access Controls
 5. Failure to Use Encryption or an Equivalent Measure to Safeguard ePHI on Portable Devices
 6. Exceeding the 60-Day Deadline for Issuing Breach Notifications
 7. Improper Disposal of PHI



US State Privacy Legislation Tracker 2023

STATUTE/BILL IN LEGISLATIVE PROCESS

- Introduced
- In committee
- In cross chamber
- In cross committee
- Passed
- Signed
- Inactive bills
- No comprehensive bills introduced



🔄 Last updated: 8/4/2023



General Data Protection Regulation (GDPR)



August 23, 2023

Why the New EU-U.S. Data Privacy Framework May Be Good News for Life Sciences Companies in the U.S.

Wim Nauwelaerts

Alston & Bird



ALSTON & BIRD

BACKGROUND

U.S.-based life sciences companies can be subject to the European Union ('EU') General Data Protection Regulation ('GDPR'), even if they do not have any subsidiary, affiliate or other physical presence in the EU. This can be the case if, for



Federal Trade Commission (FTC)



- Protects consumers' health privacy
- Focus on large-scale events
- Lawyer up!

FTC fines drug discount app for sharing user information to Facebook and Google

It's the agency's first enforcement action under its Health Breach Notification Rule.



Mariella Moon

Contributing Reporter

Updated Fri, Feb 3, 2023 · 3 min read



Modern FDA Requirements

(4) comply with such other requirements as the Secretary may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecure.

FDA official: Draft cybersecurity guidance has 'teeth'

Not following the guidance in premarket submissions means potential delays for device makers, said Suzanne Schwartz, director of CDRH's Office of Strategic Partnerships and Technology Innovation.

Published April 11, 2022

<https://www.medtechdive.com/news/fda-draft-cybersecurity-guidance-requirements/621872/>

II. Policy

Effective March 29, 2023, the FD&C Act is amended to include section 524B "Ensuring Cybersecurity of Devices." Among section 524B's cybersecurity provisions are:

(a) IN GENERAL.—A person who submits an application or submission under section 510(k), 513, 515(c), 515(f), or 520(m) for a device that meets the definition of a cyber device under this section shall include such information as [FDA] may require to ensure that such cyber device meets the cybersecurity requirements under subsection (b).

(b) The sponsor of an application or submission described in subsection (a) shall—
(1) submit to the Secretary a plan to monitor, identify, and address, as appropriate,

vulnerabilities, and
(B) as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks;

(3) provide to the Secretary a software bill of materials, including commercial, open-source, and off-the-shelf software components; and

(4) comply with such other requirements as the Secretary may require through regulation to demonstrate reasonable assurance that the device and related systems are cybersecure.

(c) DEFINITION.—In this section, the term "cyber device" means a device that—

(1) includes software validated, installed, or authorized by the sponsor as a device or in a device;

(2) has the ability to connect to the internet; and

(3) contains any such technological characteristics validated, installed, or authorized by the sponsor that could be vulnerable to cybersecurity threats.

For premarket submissions submitted for cyber devices before October 1, 2023, FDA generally intends not to issue "refuse to accept" (RTA) decisions based solely on information required by section 524B of the FD&C Act. Instead, FDA intends to work collaboratively with sponsors of such premarket submissions as part of the interactive and/or deficiency review process. Beginning October 1, 2023, FDA expects that sponsors of cyber devices will have had sufficient time to prepare premarket submissions that contain information required by section 524B of the FD&C Act, and FDA may RTA premarket submissions that do not. For information about FDA's RTA policy more generally, sponsors of cyber devices should consult FDA's guidance documents, [Refuse to Accept Policy for 510\(k\)s, Acceptance and Filing Reviews for Premarket Approval Applications \(PMA\)s](#),² and [Acceptance Review for De Novo Classification Requests](#).³

Myth:
The Premarket
Guidance must be
followed verbatim

BUSTED

Guidance

- FDA's opinion of easiest path to demonstrate reasonable assurance of cybersecurity to them
- MDMs do not necessarily have to follow this but will then have to justify their decisions
- Make your life easier with recognized standards and the discussed documentation

FDA Search Menu

IN THIS SECTION

← [Digital Health Center of Excellence](#)

Cybersecurity in Medical Devices Frequently Asked Questions (FAQs)

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

cybersecurity functions to include in the device design, and cybersecurity documentation for premarket submissions.

In addition, the FDA has recognized consensus standards, including AAMI/UL 2900-1:2017 and IEC 81001-5-1: 2021, which may be helpful to support cybersecurity documentation in submissions.

Secure Product Development Framework

- Heavy plan and procedure requirements
- IEC 81001-5-1:2021 Activities in the product life cycle
- Many other frameworks to build off of IEC 81001 for SPDF



2022 Draft Premarket Requirements

- Security Risk Management Plan
 - Including Pre- & Postmarket activities
- Threat Modeling
 - System wide plus supply chain, transfer, deployment, updating, decommissioning
- Security Requirements
- Security Architecture
 - Security Architecture Views of global system, multi-patient harm, updating, security use cases
- SBOM Generation & Processes
- Commercial Device/OS Hardening
- MDM Configuration & Deployment

4. Security Risk Management Documentation

To help demonstrate the safety and effectiveness of the device, manufacturers should provide the outputs of their security risk management processes in their premarket submissions, including their security risk management plan and security risk management report. A plan and report such as described in Section V.A.4. (pages 14-15)

1. Threat Modeling

Threat modeling includes a process for identifying security objectives, risks, and vulnerabilities across the system, and then defining countermeasures to prevent, or mitigate the effects of, threats to the system throughout its lifecycle. It is foundational for optimizing system, product, network, application, and connection security when applied appropriately and comprehensively.

Section V.A.1. (page 10)

FDA recommends that these procedures include design requirements and acceptance criteria for the security features built into the device such that they holistically address the cybersecurity considerations for the device and the system in which the device operates.

Section V.B.1. (pages 17-18)

2. Security Architecture Views

In addition to the design control requirements (i.e., 21 CFR 820.30(b), 21 CFR 820.30(c), 21 CFR 820.30(d), and 21 CFR 820.30(g)) outlined above for Security Architecture, 21 CFR 820.100 requires that manufacturers establish policies, procedures, and other plans as appropriate

Section V.B.2. (pages 19-22)

(a) Software Bill of Materials

A Software Bill of Materials (SBOM) can aid in the management of cybersecurity risks that exist throughout the software stack. A robust SBOM includes both the device manufacturer-developed components and third-party components (including purchased/licensed software and

Section V.A.2. (pages 11-14)

2022 Draft Premarket Requirements

- Security Testing
 - Attack Surface Analysis
 - Vulnerability Scanning/Testing
 - Configuration Assessment
 - Static Analysis Security Testing
 - Software Anomaly Testing
 - Malformed Input and Fuzz Testing
 - Penetration Testing
 - Coexistence of Performance & Mitigations Testing
 - Effectiveness of Controls Testing

Security testing documentation and any associated reports or assessments should be submitted in the premarket submission. FDA recommends that the following types of testing, among others, be provided in the submission:

- a. Security requirements
 - Manufacturers should provide evidence that each design input requirement was implemented successfully.
 - Manufacturers should provide evidence of their boundary analysis and rationale for their boundary assumptions.
- b. Threat mitigation
 - Manufacturers should provide details and evidence of testing that demonstrates effective risk control measures according to the threat models provided in the system, use case, and call-flow views.
 - Manufacturers should ensure the adequacy of each cybersecurity risk control (e.g., security effectiveness in enforcing the specified security policy, performance for maximum traffic conditions, stability and reliability, as appropriate).
- c. Vulnerability Testing (such as section 9.4 of ANSI/ISA 62443-4-1)
 - Manufacturers should provide details and evidence⁴⁶ of the following testing pertaining to known vulnerabilities:
 - Abuse case, malformed, and unexpected inputs,
 - Robustness
 - Fuzz testing
 - Attack surface analysis,
 - Vulnerability chaining,
 - Closed box testing of known vulnerability scanning,
 - Software composition analysis of binary executable files, and
 - Static and dynamic code analysis, including testing for credentials that are “hardcoded,” default, easily-guessed, and easily compromised.
- d. Penetration testing
 - The testing should identify and characterize security-related issues via tests that focus on discovering and exploiting security vulnerabilities in the product. Penetration test reports should be provided and include the following elements:
 - Independence and technical expertise of testers,
 - Scope of testing,
 - Duration of testing,
 - Testing methods employed, and
 - Test results, findings, and observations.

2022 Draft Premarket Requirements

- Cybersecurity Traceability
 - Security Risks, Controls & Testing
- Supply Chain Vendor Cybersecurity Assessment
- Third-Party Component Management & Mitigating Controls
- Security Content for IFU / Labeling
- MDS2 Form
- Security Risk Management Report

The security risk management report should:

- summarize the risk evaluation methods and processes, detail the security risk assessment, and detail the risk mitigation activities undertaken as part of a manufacturer's risk management processes; and
- provide traceability between the security risks, controls and the testing reports that ensure the device is reasonably secure.

Section V.A.4. (page 15)

In addition, under 21 CFR 820.50, manufacturers must put in place processes and controls to ensure that their suppliers conform to the manufacturer's requirements. Such information is documented in the Design History File, required by 21 CFR 820.30(j), and Design Master Record, required by 21 CFR 820.181. This documentation demonstrates the device's overall

Section V.A.2. (pages 11-14)

A. Labeling Recommendations for Devices with Cybersecurity Risks

FDA regulates device labeling in several ways. For example, section 502(f) of the FD&C Act requires that labeling include adequate directions for use. Under section 502(a)(1) of the FD&C Act, a medical device is deemed misbranded if its labeling is false or misleading in any particular.


Section VI.A. (pages 24-25)

A revision-controlled, Manufacturer Disclosure Statement for Medical Device Security (MDS2) and Customer Security Documentation as outlined in the HSCC Joint Security Plan (JSP) may address a number of the above recommendations.

Section VI.A. (pages 26)

To the Future

- Expecting final premarket guidance to be updated in a matter of weeks
 - Language to change but content to remain similar
- Additional eSTAR updates shortly after
- Annual cadence of FDA and CISA working together to define current best practices
- Forthcoming Postmarket guidance updates



**THANK
YOU**



Threat Modeling

1. What are we working on?
2. What can go wrong?
3. What are we going to do about it?
4. Did we do a good enough job?




**THREAT
MODELING
MANIFESTO**

Malformed Input and Fuzz Testing

- Injecting malformed, invalid or unexpected inputs into systems
- “Zero-day” discovery
- Robustness testing




Penetration Testing, Hardening, Configuration Assessment and More...



Secure Code Static Analysis

- 93 billion lines of code written in 2020
 - Out of ~3 trillion lines total
- Errors per 1000 lines of code
 - Industry average 15–50 per 1000
 - The “best” teams get to 1–5 per 1000
- So lets call it 10 per 1000...
 - 30 billion bugs ever written!
 - 930 million bugs created in 2020 alone




SBOMs & Post-Market Surveillance

```

26 },
27 "components": [
28 {
29   "type": "library",
30   "bom-ref": "99369316-8a12-6228-230e-8dcca99d484",
31   "name": "Dinkum C/C++ Library",
32   "purl": "pkg:supplier/Dinkum/Dinkum%20C%2FC%2B%2B%20Library@TBD",
33   "publisher": "Dinkum",
34   "version": "TBD"
35 },
36 {
37   "type": "library",
38   "bom-ref": "7fbee16-6ebb-236f-b486-3023b54f9436",
39   "name": "FreeRTOS",
40   "purl": "pkg:supplier/Amazon%20Web%20Services/FreeRTOS@10.3.1",
41   "publisher": "Amazon Web Services",
42   "version": "10.3.1"
43 },
44 {
45   "type": "library",
46   "bom-ref": "5e6155a5-6d1e-b059-5db8-ad172c81edc4",
47   "name": "BlueNRG1 Bluetooth Stack/SDK",
48   "purl": "pkg:supplier/STMicroelectronics/BlueNRG1%20Bluetooth%20Stack%2FSDK@3.2.1",
49   "publisher": "STMicroelectronics",
50   "version": "3.2.1"
51 },
52 {
53   "type": "library",
54   "bom-ref": "827da811-fdfa-d1c0-16dd-21969dcd17ee",
55   "name": "STM32Cube MCU Package",
56   "purl": "pkg:supplier/STMicroelectronics/STM32Cube%20MCU%20Package@1.6.1",
57   "publisher": "STMicroelectronics",
58   "version": "1.6.1"
59 },
60 {
61   "type": "library",
62   "bom-ref": "fb3a91a5-50ba-2599-b053-a1401a691564",
63   "name": "EmCrypt Cryptographic Library",
64   "purl": "pkg:supplier/SEGGER%20Microcontroller/EmCrypt%20Cryptographic%20Library@2.38.0",
65   "publisher": "SEGGER Microcontroller",
66   "version": "2.38.0"
67 }
68 ],
69 "dependencies": [
70 {

```




SBOMs & Post-Market Surveillance

```
"type": "library",  
"bom-ref": "7fbeec16-6ebb-236f-b486-3023b54f9436",  
"name": "FreeRTOS",  
"purl": "pkg:supplier/Amazon%20Web%20Services/FreeRTOS@10.3.1",  
"publisher": "Amazon Web Services",  
"version": "10.3.1"
```

Commercial Vulnerability

For all software in




Commercial Vulnerability Scanners and Aggregators

For all software in the repository

Individual Vulnerabilities

Security Bulletins




SBOMs & Post-Market Surveillance

```

26 },
27 "components": [
28 {
29   "type": "library",
30   "bom-ref": "99369316-8a12-6228-230e-8dcca99d484",
31   "name": "Dinkum C/C++ Library",
32   "purl": "pkg:supplier/Dinkum/Dinkum%20C%2FC%2B%2B%20Library@TBD",
33   "publisher": "Dinkum",
34   "version": "TBD"
35 },
36 {
37   "type": "library",
38   "bom-ref": "7fbee16-6ebb-236f-b486-3023b54f9436",
39   "name": "FreeRTOS",
40   "purl": "pkg:supplier/Amazon%20Web%20Services/FreeRTOS@10.3.1",
41   "publisher": "Amazon Web Services",
42   "version": "10.3.1"
43 },
44 {
45   "type": "library",
46   "bom-ref": "5e6155a5-6d1e-b059-5db8-ad172c81edc4",
47   "name": "BlueNRG1 Bluetooth Stack/SDK",
48   "purl": "pkg:supplier/STMicroelectronics/BlueNRG1%20Bluetooth%20Stack%2FSDK@3.2.1",
49   "publisher": "STMicroelectronics",
50   "version": "3.2.1"
51 },
52 {
53   "type": "library",
54   "bom-ref": "827da811-fdfa-d1c0-16dd-21969dcd17ee",
55   "name": "STM32Cube MCU Package",
56   "purl": "pkg:supplier/STMicroelectronics/STM32Cube%20MCU%20Package@1.6.1",
57   "publisher": "STMicroelectronics",
58   "version": "1.6.1"
59 },
60 {
61   "type": "library",
62   "bom-ref": "fb3a91a5-50ba-2599-b053-a1401a691564",
63   "name": "EmCrypt Cryptographic Library",
64   "purl": "pkg:supplier/SEGGER%20Microcontroller/EmCrypt%20Cryptographic%20Library@2.38.0",
65   "publisher": "SEGGER Microcontroller",
66   "version": "2.38.0"
67 }
68 ],
69 "dependencies": [
70 {

```



VI. Labeling Recommendations for Devices with Cybersecurity Risks

- Instructions and product specifications
- Features that protect critical functionality
- Backup and restore info
- Guidance for supporting infrastructure
- Device hardening
- Software update info
- End-of-support info
- Communication interfaces and networking info
- Security event notifications
- Forensic evidence capture (secure logging)
- Diagrams
- SBOM

